Xvivo Perfusion AB (publ)
0RKL.L
London Stock Exchange284.20
SEK
+0.20
- -
Xvivo Perfusion AB (publ)
0RKL.L
(London Stock Exchange)
Recent
price
284.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Xvivo Perfusion AB (publ) develops and commercializes perfusion technologies and services to enhance organ preservation and transplantation outcomes for lungs, livers, kidneys, and hearts; core products include the XPS system with STEEN Solution and disposable kits for ex vivo lung perfusion (EVLP), Kidney Assist and Kidney Assist Transport for hypothermic oxygenated perfusion (HOPE) of kidneys, Liver Assist for hypothermic, normothermic, or sub-normothermic liver perfusion, PERFADEX Plus for cold static lung preservation, and heart perfusion technology comprising a machine, disposables, and specialized solution. Founded in 1998 and headquartered in Mölndal, Sweden, the company operates through thoracic, abdominal, and services segments, serving transplant centers and hospitals primarily in North America, Europe (including Italy), and internationally with subsidiaries supporting organ recovery such as Star Teams in the US and perfusion services in Italy. Recent developments encompass the October 2024 acquisition of FlowHawk, a HIPAA-compliant communication platform strengthening US transplant coordination services, completion of US clinical trial enrollment for heart technology in November 2024 ahead of anticipated CE marking and European launch in the first half of 2025, accelerated Kidney Assist Transport installations across over 15 high-volume European hospitals in 2024 supported by clinical evidence from The Lancet, and a strategic 2025 focus on North American EVLP expansion alongside European heart technology rollout.